Answers are grounded in this paper and cite their sources.
Chronic kidney disease (CKD) is increasingly recognised as a systemic disorder in which a bidirectional host–microbiota relationship contributes to disease progression. This review is deliberately restricted in scope to the microbial metabolites for which mechanistic and clinical evidence is most developed: the protein-bound uremic solutes indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), and the microbiota-derived co-metabolite trimethylamine N-oxide (TMAO). These harmful metabolites are explicitly contrasted with short-chain fatty acids (SCFAs), the principal class of beneficial microbial metabolites, whose depletion represents a loss of reno-protection rather than a gain of toxicity. In CKD, the colonic milieu is reshaped by urea influx, restricted fruit, vegetable and fibre intake, slowed intestinal transit and repeated antibiotic and phosphate-binder exposure; the resulting dysbiosis favours proteolytic fermentation and the generation of indole and p-cresol, which undergo hepatic and intestinal phase II conjugation to IS and p-CS, while choline- and carnitine-derived trimethylamine is oxidised by hepatic flavin monooxygenase 3 to TMAO. Because these solutes are highly protein-bound, they are poorly cleared by conventional haemodialysis and accumulate as renal function declines. At the molecular level, IS is a well-characterised (AhR), and AhR activation, NADPH-oxidase-derived reactive oxygen species, NF-κB-dependent cytokine transcription and TGF-β1/Smad3-driven matrix deposition together form the best-supported injury cascade; other links, notably metabolite-directed epigenetic remodelling, remain hypothesis-generating. Therapeutic strategies are appraised according to their development stage and the strength of the evidence behind them, from the oral adsorbent AST-120 - whose pivotal EPPIC trials did not meet their primary endpoint - through investigational microbial enzyme inhibitors to experimental AhR antagonists. We argue that the field’s central unmet need is not further descriptive mechanistic work but biomarker-enriched, adequately powered and earlier-initiated clinical trials capable of distinguishing metabolite lowering from clinical benefit.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: